- Joined
- May 3, 2004
- Messages
- 12,250
- Reaction score
- 2,868
Prices tumble for debt backing KKR’s $9.9bn Envision buyout
Healthcare provider stumbles as support grows for medical billing reform
www.ft.com
IMO this is more about the future of EM and much less about the view of the crappy nature of debt held by CMGs though with the price discrepancy thats a part of it.
The debt backing KKR’s $9.9bn buyout last year of Envision Healthcare has tumbled in value, reflecting investor fears that greater government scrutiny of US medical billing practices could reduce the company’s revenues. Fitch, the rating agency, highlighted the concerns this week, placing the company’s $5.4bn loan on its list of “struggling” deals, in another sign of the cracks emerging in the $1.4tn leveraged loan market. There are now $94.1bn of loans on the Fitch list, up from $74.5bn in July. Envision is the biggest of the 114 loans on the list, which is based on a loan’s rating, its market price and “adverse market information”. There is uncertainty and that hurts the loan price because there aren’t many people wanting to buy the debt Ron Launsbach, a senior portfolio manager at asset manager Columbia Threadneedle Last year’s deal for Envision — a supplier of medical staff to US hospitals and clinics — was one of the biggest buyouts since the financial crisis, and was criticised by some debt market analysts for a lack of investor protections. “[Envision] was a very aggressive deal,” said one loan investor. “The deal got done at the top of the market when everyone had money they needed to put to work.” Envision’s $5.4bn loan maturing in 2025 has fallen from 86.2 cents on the dollar at the start of August to 77.3 cents on the dollar on Wednesday, compared with a decline from 97.1 cents on the dollar to 96.3 cents on the dollar for the broader market. A $1.2bn bond sold by the company dropped from almost 71 cents on the dollar to just over 54.9 cents on the dollar over the same period. The debt came under pressure after bipartisan support emerged in Congress for bills that would prevent patients from being hit with unexpectedly large charges though a practice known as “surprise billing”. In such cases, patients seek treatment at an “in-network” facility covered by their insurance but wind up being treated by a “out-of-network” doctor, such as those employed by Envision. These doctors typically try to recoup costs from the patient’s insurer but often end up passing them on to the patient. “If revenues fall for the providers then we could run into a cash flow problem with all of this debt,” said Ron Launsbach, a senior portfolio manager at asset manager Columbia Threadneedle. “Clearly there is uncertainty and that hurts the loan price because there aren’t many people wanting to buy the debt.” Recommended Loan funds on course for worst outflows on record Fitch also added a $2.7bn loan from Blackstone-backed TeamHealth, another large healthcare provider, to its list of struggling deals. That loan’s price has sunk from 87.6 cents on the dollar to 80.8 cents on the dollar this month. Moody’s changed its outlook for TeamHealth to negative this month, reflecting the rating agency’s uncertainty over the company’s ability to reduce its 8.2 times debt to Ebitda (earnings before interest, taxes, depreciation and amortisation) leverage after insurer UnitedHealth terminated two-thirds of its in-network contracts with the healthcare provider and “significantly reduced” payments for out-of-network services. Envision declined to comment. TeamHealth said it had been successful in getting “reasonable reimbursements” for the treatment it provides, adding: “We expect to be successful in those efforts going forward.”